AstraZeneca Reaffirms 2025 Guidance: Expects High Single-Digit Revenue Growth, Low Double-Digit Core EPS Growth, And 18

AstraZeneca Reaffirms 2025 Guidance: Expects High Single-Digit Revenue Growth, Low Double-Digit Core EPS Growth, And 18–22% Core Tax Rate

-0.51%

Astrazeneca PLC Sponsored ADR

AZN

89.83

-0.51%

Guidance AstraZeneca reiterates its Total Revenue and Core EPS guidance for FY 2025 at CER, based on the average foreign exchange rates through 2024.

Total Revenue is expected to increase by a high single-digit percentage

Core EPS is expected to increase by a low double-digit percentage

The Core Tax rate is expected to be between 18-22%

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.